HeartForce has finalized its analysis on the cost-effectiveness of the CardioClin within the Canadian healthcare system. By analyzing billing codes under the Ontario Health Insurance Plan (OHIP), we investigated the devices utilized in the diagnostic pathway for Coronary Artery Disease (CAD). This pathway encompasses both the bulk of individuals diagnosed with CAD and, those with stable chest pain who have not yet been diagnosed.
Our clinical studies indicate that the effectiveness of our device lies in its ability to rule out non-CAD cases. Statistical analysis reveals that employing our device can lead to a per-patient cost reduction of $280 CAD ($208 USD) within the CAD diagnosis pathway
This comprehensive report will soon be presented to the Canadian Agency for Drugs and Technologies in Health (CADTH), which signifies a step forward in securing billing code approval and Health Canada’s endorsement. HeartForce has already prepared a preliminary version of the report and is collaborating with healthcare experts and cardiologists to validate its research findings.
Need to get in touch with the team? We’re all ears.
